CSL

View our library:

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Webinar: China Pipelines, Western Portfolios (2pm GMT, July 14 | Register)
• Webinar: World Preview 2026 (Watch Now)
• Webinar: ASCO 2026 - Key Insights and Innovations (Watch Now)
• Podcast: Drug Fix - Potential Nondisclosure Agreements For US FDA Staff, Hiring Threatens User Fee Reductions (Listen)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• M&A: CVC Capital Partners Launches €10.7B Offer to Buy Recordati
• M&A: Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1B
• M&A: Bayer Enters Agreement To Acquire Perfuse Therapeutics For Up To $2.45B
• Licensing: Hengrui Pharma and Bristol Myers Squibb Enter Potential $15.2B Agreement to Advance 13 Programs Across Oncology, Hematology, and Immunology ($600M upfront)
• Licensing: Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines totalling $10.5B ($650M upfront)
• Licensing: Boston Scientific Invests $1.5B in MiRus; Gets Option to Acquire TAVR Business
• Financing: Hemab Therapeutics Nets $322M in IPO; Overallotment Exercised
• Financing: Odyssey Therapeutics Nets $259.5M in Revived IPO
• Financing: Isomorphic Labs Brings in $2B in Series B Round

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Positive: Revolution Medicines | Phase III RASolute 302 Trial Reveals Daraxonrasib's Unprecedented HR 0.40 OS Benefit in 2L mPDAC, Setting the Bar for the Pan-RAS Class
• Positive: Cogent Biosciences | PEAK delivers the first positive 2L GIST Phase 3 in 20 years, with mechanism-validated subgroups and a manageable hepatotoxicity signal
• Positive: Akeso | HARMONi-6 delivers a compelling OS benefit in squamous NSCLC, but Western generalizability remains unproven pending HARMONi-3
• Positive: BioMarin | Voxzogo Aces Phase 3 Skeletal Dysplasia Expansion, Potentially Doubling Addressable Market with Minimal Regulatory Risk
• Positive: Eli Lilly | Pivotal Phase III results for Lilly’s retatrutide demonstrate ground breaking weight loss potential in obesity
• Negative: Aardvark | FDA places full clinical hold on ARD-101 Phase 3 HERO program in Prader-Willi syndrome (PWS), triggering reassessment of development path
• Negative: Regeneron | fianlimab plus Libtayo falls behind expectations with a missed PFS mark in first-line unresectable melanoma
• Negative: Oculis | OCS-01 Phase III DIAMOND program fails to meet primary endpoint, ending regulatory path in diabetic macular edema (DME)

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Report: Annual Completed Clinical Trials Report 2026 (Link)
• Report: ASCO 2026 - Planner | Pre-ASCO | Weekend Update
• Report: Dealmaking / Financing Quarterly Statistics, Q1 2026
• Report: Q2 2026 Outlook Report
• Report: Inside the ADC Deal Surge
• Report: Diabetes Management: Blood Glucose Monitoring Devices
• Report: Epi & Market Forecast - Type-1 Diabetes | Dry Eye Disease | Multiple Sclerosis | Schizophrenia
• Report: KOL Interview - Chronic Myeloid Leukemia | Dry Eye Disease

Note: Require research support on scientific meetings not under below list? Submit your inquiry via Ask the Analyst!